Improving the lives of Type 1 diabetes patients with safer modern insulin
Silently brewing among India’s huge population of diabetics is a heartbreaking story of nearly 1.5 million patients below 20 with Type 1 diabetes. Dr Surendra Kumar Sharma, endocrinologist, Jaipur, says, “Those suffering from Type 1 diabetes are not regular patients, who can be treated with oral medicines. They require insulin injections multiple times a day just to survive. Even with advances in technology and access to newer, safer, and more effective insulin, called modern insulin (analogs), the cost of these insulin alternatives is high compared to older insulin.” The choice such patients and their families have is to continue to bear the enormous cost of modern safe insulin every day or to suffer from side effects of older and traditional insulin variants. Since these patients are very young, the economic impact on these families is three to four times the impact on other diabetes patients diagnosed later in life and managed through oral medicines. But now, few enterprising Indian firms with a global approach have taken on this human-economic cost challenge of increasing access to safer modern insulin at 50% of the cost of innovator brands. Dr Sharma says, “These companies not only save lives by offering insulin at lower cost but also ensure that the patients stay on therapy so that complications are avoided.”
Disclaimer: The veracity of any health claim made in the above article is the responsibility of the concerned hospital/doctor.
Dr Surendra Kumar Sharma, endocrinologist, Jaipur